Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Gastrointestinal cancer

Is NETTER-2 a practice-changing trial?

The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Singh, S. et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet https://doi.org/10.1016/S0140-6736(24)00701-3 (2024).

    Article  PubMed  Google Scholar 

  3. Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 33, 115–154 (2022).

    Article  CAS  PubMed  Google Scholar 

  4. Merola, E. et al. Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when Ki-67 Is ≥10%? Oncologist 26, 294–301 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968–977 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Kunz, P. L. et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J. Clin. Oncol. 41, 1359–1369 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Al-Toubah, T., Pelle, E., Valone, T., Haider, M. & Strosberg, J. R. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J. Natl. Compr. Canc. Netw. 20, 29–36 (2022).

    Article  CAS  Google Scholar 

  9. Bodei, L. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur. J. Nucl. Med. Mol. Imaging 42, 5–19 (2015).

    Article  CAS  PubMed  Google Scholar 

  10. Cordero-Hernandez, I. S. et al. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr. Relat. Cancer 31, e230203 (2024).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jonathan Strosberg.

Ethics declarations

Competing interests

J.S. has acted as a consultant of Exelixis, Harpoon Therapeutics and Novartis and has received research funding from ITM, Novartis, Radiomedix and RayzeBio. M.C. has acted as a consultant of AAA, Advanz, Esteve, Harbour Biomedical, Harpoon Therapeutics and Novartis, and has received research funding from Advanz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strosberg, J., Cives, M. Is NETTER-2 a practice-changing trial?. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00925-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41571-024-00925-8

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer